Senseonics wins another FDA approval for its implantable CGM

This article was originally published here

SenseonicsSenseonics (NYSE:SENS) said this week that it won another FDA approval for its implantable continuous glucose monitoring system, giving nurse practitioners and physicians assistants the ability to implant and remove the Eversense device.

When the product was first approved by the FDA in June, only trained physicians were allowed to conduct the sensor insertion and removal procedures.

Get the full story at our sister site, Drug Delivery Business News.

The post Senseonics wins another FDA approval for its implantable CGM appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply